At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Jul 30, 2026 at 07:30 ET
Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide public comment at an FDA public meeting on drug repurposing on August 5, 2026. This is a routine speaking engagement with no financial or regulatory impact on the company's pipeline or stock.
- Dr. Martini will provide public comment at an FDA public meeting on drug repurposing on August 5, 2026.
- The meeting is convened by the Reagan-Udall Foundation in collaboration with the FDA.
- No financial data, clinical results, or regulatory decisions were announced.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access